Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations remibrutinib - BTK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) NCT05147220 REMODEL-1 (CLOU064C12301) Multiple sclerosis Phase 3 800 Annualized relapse rate (ARR) of confirmed relapses Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Patients with relapsing Multiple Sclerosis Estimated primary completion 2025 Estimated study completion 2029 NCT05156281 REMODEL-2 (CLOU064C12302) Multiple sclerosis Phase 3 800 Annualized relapse rate (ARR) of confirmed relapses Arm 1: Experimental; Remibrutinib - Core Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide - Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib - Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Patients with relapsing Multiple Sclerosis Estimated primary completion 2025 Estimated study completion 2029 Publication TBD 100 Investor Relations | Q4 2021 Results TBD 1 NOVARTIS | Reimagining Medicine

View entire presentation